There is a growing body of evidence to suggest a relationship between cigarette smoking and increased breast cancer risk. Components of cigarette smoke have been detected in fluid from breast ducts of smokers ([@bib37]; [@bib21]), and smoking has been associated with a higher level of DNA adducts ([@bib36]; [@bib24]), higher prevalence of *TP53* mutations and p53 overexpression in breast tumours ([@bib11]; [@bib5]), providing a plausible hypothesis for a biological link between smoking and risk. Yet, epidemiologic evidence has been mixed. The majority of studies have used a case--control design and reported a mixture of positive, null, and inverse associations ([@bib41]). But as noted by Terry and Rohan ([@bib41]), case--control analyses of smoking may be subject to differential recall bias; prospective assessments of smoking avoid this bias and therefore may be more appropriate. While early prospective studies reported a mixture of positive ([@bib19]) and null ([@bib20]; [@bib39]; [@bib9]; [@bib33]) associations, more recent cohort studies have reported positive associations, with relative risks ranging from 1.08 to 1.70 for current smoking and 1.00 to 1.34 for former smoking ([@bib29]; [@bib2]; [@bib38]; [@bib15]; [@bib18]; [@bib35]; [@bib6]; [@bib16]; [@bib44]; [@bib27]; [@bib12]).

Reasons for the variation in association among prospective studies are unclear, but potential causes include confounding or effect measure modification. Most recent studies have adjusted for potential confounders in regression models, but it is possible that residual confounding could affect the association between smoking and risk ([@bib17]). Alcohol use, in particular, has been identified as a potential source of residual confounding due to the positive correlation between alcohol use and smoking ([@bib31]) and the association between alcohol and increased breast cancer risk ([@bib17]; [@bib7]). In a recent study, [@bib12] presented associations stratified by alcohol use status (never, former, current) but did not include information on the amount of alcohol consumed. As such, it is unclear whether associations among current and former drinkers are subject to residual confounding by the amount of alcohol consumed.

Limited prospective data also suggest that there may be differences in smoking-associated risk according to body mass index (BMI) and family history of breast cancer. In one study, smoking was associated with increased risk in non-obese women while there was no association among obese women ([@bib26]). In another, smoking-associated risk was stronger among women without a family history of breast cancer when compared with women with a family history ([@bib38]). However, there was no modification by BMI or family history in other studies ([@bib15]; [@bib6]; [@bib12]). There are also data to suggest that the smoking association with risk is elevated among current and former alcohol drinkers but not among non-drinkers ([@bib25]; [@bib12]), but these differences were not statistically significant and other studies have found no modification by alcohol use ([@bib15]; [@bib6]). Analyses involving menopausal status ([@bib38]; [@bib15]; [@bib6]), menopausal hormone therapy (MHT) use ([@bib6]; [@bib12]), age ([@bib15]), age at menarche ([@bib6]), parity ([@bib15]; [@bib6]), age at first birth ([@bib15]), and benign breast disease ([@bib6]) suggest that these factors do not modify the association between smoking and risk, but these factors have been examined in a limited number of studies.

To clarify our understanding of the relationship between smoking and breast cancer risk, we examined the association using data from the National Institutes of Health (NIH)-AARP Diet and Health Study, a large prospective cohort study that has previously demonstrated breast cancer risk relationships for a variety of factors that could potentially confound or modify associations with cigarette smoking ([@bib1]; [@bib4]; [@bib23]; [@bib34]). Additionally, we examined whether smoking was related to the risk of specific subgroups of breast cancer, defined by disease stage at diagnosis, histology, hormone receptor expression, and tumour grade.

Materials and Methods
=====================

Study population
----------------

The NIH-AARP Diet and Health Study has been described previously ([@bib40]). Briefly, in 1995--1996 a questionnaire regarding health and nutrition was sent to members of AARP (formerly American Association of Retired Persons) who were 50--71 years old and living in California, Florida, Louisiana, New Jersey, North Carolina, Pennsylvania, Atlanta, Georgia, and Detroit, Michigan. The study was approved by the Special Studies Institutional Review Board of the National Cancer Institute. Completion of the questionnaire implied informed consent.

Of 617 119 questionnaires returned, 567 169 were completed satisfactorily ([@bib40]). For this analysis, we excluded responses that were duplicates (*N*=179) or completed by proxy (*N*=15 760). We also excluded respondents who were male (*N*=325 172), had prevalent cancer (*N*=23 961), moved from the study area or died before the questionnaire was returned (*N*=592), were premenopausal or had unknown menopausal status (*N*=9420), withdrew from the study (*N*=9), or did not provide smoking information (N=5926), resulting in 186 150 postmenopausal women in the analytic cohort ([Figure 1](#fig1){ref-type="fig"}).

Risk factors
------------

At enrolment, participants were asked whether they had smoked ⩾100 cigarettes during their lifetime, whether they currently smoked, when they stopped smoking, and the number of cigarettes they usually smoked per day. Smoking status was defined as follows: participants who had not smoked ⩾100 cigarettes were classified as never smokers; participants who had smoked ⩾100 cigarettes and either currently smoked or quit within 1 year of enrolment were classified as current smokers; and participants who had smoked ⩾100 cigarettes but stopped smoking \>1 year prior to study enrolment were classified as former smokers.

Type of menopause was determined from the reason menstrual periods stopped, whether the ovaries had been removed, and age at last menstrual period. MHT use was determined from questions regarding how long women used 'replacement hormones\' and whether they were currently using hormones. Body mass index was calculated as weight (kilograms) divided by squared height (metres). Frequency of vigorous physical activity was defined by how often women participated in exercise, sports, or carrying heavy loads that increased sweating, breathing, or heart rate and lasted ⩾20 min. Alcohol use (grams per day) was estimated from the frequency and amount of beer, wine, and liquor consumed ([@bib23]). Family history of breast cancer was based on history in a first-degree female relative. Other covariates included age at menarche, age at first birth, previous breast biopsy, education level, and race/ethnicity. Data were missing for \<5% of participants for all variables.

Cohort follow-up
----------------

Participants were followed for changes of address using data from the US Postal Service, other address update services, and participant updates. Vital status was determined through periodic linkage to the Social Security Administration Death Master File, responses to study mailings, National Death Index searches, and cancer registry linkages. Follow-up time was calculated from the date the questionnaire was returned through the earliest of the following: breast cancer diagnosis, movement out of the registry ascertainment area, death, or 31 December 2006. 12 790 (7%) women moved from the registry ascertainment area prior to the end of follow-up; these women were younger and more educated than the rest of the cohort, but had similar distributions of smoking status and other risk factors.

Case ascertainment
------------------

Cancer diagnoses were obtained from state cancer registries in the eight study areas plus the adjacent states of Texas, Arizona, and Nevada ([@bib30]). A validation study comparing registry findings with self-reports and medical records estimated that linkage identified 90% of incident cancers ([@bib30]). Cases were defined as primary invasive breast cancers diagnosed after study enrolment. Histology, defined using the International Classification of Diseases for Oncology ([@bib10]), tumour grade, hormone receptor expression, and disease stage, defined by the Surveillance, Epidemiology, and End Results (SEER) Program summary staging definitions ([@bib45]), were obtained from cancer registry records. Disease stage at diagnosis was classified as localised if the disease was confined to the breast tissue and breast fat; regional spread if the disease had spread to adjacent tissues by direct extension and/or spread to the regional lymph nodes; or distant metastases if the disease had spread to non-adjacent organ sites. Hormone receptor data were reported by California, Louisiana, New Jersey, North Carolina, Arizona, Nevada, Georgia, and Michigan registries; these states ascertained 64% of the study\'s breast cancer cases.

Statistical analysis
--------------------

Time-dependent interactions between each variable and age during follow-up were tested for significance to establish that hazards were proportional over time (all *P*\>0.05). We estimated multivariable-adjusted hazard ratios (HR) and 95% confidence intervals (CI) for the association between smoking status, number of cigarettes smoked, and time since quitting smoking and breast cancer risk using Cox proportional hazards regression in SAS v9.2 (SAS, Cary, NC, USA); age was the underlying timescale. Models were adjusted for age at enrolment (continuous), race/ethnicity (white non-Hispanic, other), education level (high school or less, vocational/some college, college graduate, postgraduate), age at menarche (⩽12, 13--14, ⩾15 years), age at first birth (nulliparous, \<20, 20--24, 25--29, ⩾30 years), type of menopause (natural menopause at \<45, 45--49, 50--54, ⩾55 years, bilateral oophorectomy, other surgery, medical/unknown age at natural menopause), MHT use (never, former, current), BMI in quartiles (\<22.9, 22.9--25.7, 25.8--29.6, \>29.6 kg m^−2^), alcohol consumption (0, \>0--5, \>5--10, \>10--20, \>20--35, \>35 g per day), frequency of vigorous physical activity (never/rarely, 1--3 times per month, 1--2 times per week, 3--4 times per week, ⩾5 times per week), previous breast biopsy (no, yes), and family history of breast cancer (no, yes). To further evaluate confounding by the amount of alcohol consumed, we also estimated smoking associations within strata of alcohol consumption. Formal tests of linear trend for number of cigarettes and time since quitting were conducted by modelling exposure categories as ordinal variables among smokers only.

Effect measure modification by BMI (\<30, ⩾30 kg m^−2^), family history of breast cancer (no, yes), alcohol consumption (⩽5 g per day, \>5 g per day), type of menopause (natural at \<50 years, natural at ⩾50 years, bilateral oophorectomy, other surgical or medical menopause), MHT use (never, former, current), age at menarche (⩽12, 13--14, ⩾15 years), age at first birth (nulliparous, \<25, ⩾25 years), previous breast biopsy (yes, no), and age at baseline (\<55, 55--59, 60--64, ⩾65 years) was evaluated using the same categorisations used in previous studies that reported interaction with these factors ([@bib43]; [@bib42]; [@bib28]; [@bib26]) or categorisations associated with breast cancer risk. We also evaluated alternative categorisations for BMI and MHT using categorisations used in prior studies (BMI: ⩽24, \>24 kg m^−2^; MHT: never, ever) ([@bib43]; [@bib42]). We constructed risk estimates for smoking status stratified by these factors and additionally compared multivariable-adjusted models with and without multiplicative interaction terms using the likelihood ratio test. Tests were two-sided and *P*-values \<0.05 were considered statistically significant. The expected joint HR under the multiplicative null was calculated by multiplying the HR associated with only smoking (unexposed to the potential modifier) and the HR associated with only being exposed to the potential modifier (unexposed to smoking).

Associations between smoking and risk were estimated for specific breast cancer types, defined by disease stage, histology, oestrogen and progesterone receptor (ER, PR) expression, and tumour grade. Tests of statistical heterogeneity among tumour types were performed using case-only logistic regression. Risk of ER/PR-defined tumours was evaluated using data only from participants that lived in states where registries collected hormone receptor data.

To evaluate whether the presence of smoking-related health conditions affected the relationship with risk, we examined models that excluded women with self-reported poor health or emphysema and compared those results to the main analysis. We also estimated associations for the first and second halves of the follow-up period to address the possibility that changes in health characteristics or behaviours during the follow-up period affected risk estimates. For the first half of follow-up, person-time was truncated 5 years after enrolment and cases occurring after that time were censored. For the second half of follow-up, only person-time and incident cases occurring \>5 years after enrolment were analysed.

A subsequent questionnaire mailed in 2004--2006 obtained additional information, including the age when participants started smoking. Of 186 150 women in the baseline cohort, 90 950 (49%) provided additional smoking information in 2004--2006. We attempted to explore whether age at smoking initiation was associated with risk in this sub-cohort of women, but found that the association between smoking status and risk in the subgroup was null, potentially due to limited follow-up, lack of power, or selection bias. Therefore, age at smoking initiation was not included in further analyses.

Results
=======

A total of 186 150 women were followed for a mean of 9.6 years (standard deviation---2.5); 17% were current smokers, 38% were former smokers, and 45% had never smoked ([Supplementary Table 1](#sup1){ref-type="supplementary-material"}). A total of 7481 breast cancers were diagnosed during follow-up. Breast cancer risk was elevated among current and former smokers as compared with never smokers (current, HR 1.19, 95% CI 1.10--1.28; former, HR 1.07, 95% CI 1.01--1.13; [Table 1](#tbl1){ref-type="table"}). There was no clear dose--response relationship between number of cigarettes smoked per day and risk among current or former smokers, nor was there a dose--response trend with time since quitting. Risk for former smokers remained slightly elevated when compared with never smokers, even for those who quit ⩾10 years prior to baseline (HR 1.04, 95% CI 0.98--1.11).

To explore whether associations between smoking status and risk might be due to confounding by alcohol consumption, we estimated associations within strata of alcohol consumption and found that the association remained elevated across strata ([Supplementary Table 2](#sup1){ref-type="supplementary-material"}). Notably, current smoking was suggestive of increased risk even among women who did not drink alcohol (HR 1.14, 95% CI 0.98--1.32).

We next examined how the association between smoking status and risk varied across strata of other risk factors ([Figure 2](#fig2){ref-type="fig"}). The association between current smoking and risk was stronger among women with BMI \<30, without a family history of breast cancer, who reached menarche at ⩾15 years old, who drank ⩾5 g alcohol per day, who experienced natural menopause, who were not currently using menopausal hormones, and who were \<55 years old at baseline. These differences were more pronounced for current rather than former smoking. With respect to alcohol consumption, smoking associations with risk did not differ when we separated the stratum of women who drank ⩽5 g per day into 0 g and \>0 to 5 g per day ([Supplementary Table 2](#sup1){ref-type="supplementary-material"}). Smoking-associated risks did not differ notably by age at first birth or previous breast biopsy ([Figure 2](#fig2){ref-type="fig"}). The results did not change when we used alternative categorisations for BMI (⩽24, \>24 kg m^−2^) or MHT use (never, ever) used in previous studies ([Supplementary Table 3](#sup1){ref-type="supplementary-material"}).

Tests of multiplicative interaction with smoking status were significant only for family history of breast cancer (*P*-interaction=0.03) and age at menarche (*P*-interaction=0.03). When we examined their joint associations with smoking, the increased risk due to current smoking among women with a family history (HR 1.49, CI 1.27--1.75) was lower than the expected joint association under the multiplicative null (expected HR=1.93) ([Table 2](#tbl2){ref-type="table"}). The joint HR for former smokers was 1.60 (CI 1.45, 1.77), similar to the expected HR of 1.68. With regards to the joint association between smoking and age at menarche, current smokers who reached menarche at ⩾15 years had 1.21 (95% CI 0.99--1.47) times the risk of never smokers who reached menarche at ⩽12 years, an association that was qualitatively different from the expected joint HR of 0.88 ([Table 3](#tbl3){ref-type="table"}).

There were no strong differences when we examined risk of specific breast cancer types. Although current and former smoking were associated more strongly with distant metastases (current HR 2.05, CI 1.30--3.23; former HR 1.56, CI 1.06--2.30) than localised (current HR 1.21, CI 1.09--1.34; former HR 1.07, CI 0.99--1.16) or regional spread (current HR 1.18, CI 0.99--1.41; former HR 1.10, CI 0.96--1.26), these differences were not significantly different (*P*-heterogeneity=0.22; [Table 4](#tbl4){ref-type="table"}). Associations with current, but not former, smoking were slightly stronger for lobular rather than ductal or mixed ductal-lobular tumours (*P*-heterogeneity=0.55) and for ER+/PR− rather than ER+/PR+ or ER−/PR− tumours (*P*-heterogeneity=0.40). There were no differences in smoking-associated risk by tumour grade (*P*-heterogeneity=0.90).

Associations between smoking status and risk were similar after excluding women who had emphysema or poor health, and also for the first and second halves of follow-up ([Supplementary Table 4](#sup1){ref-type="supplementary-material"}).

Discussion
==========

In the NIH-AARP Diet and Health study, current and former smokers had greater risk of breast cancer when compared with never smokers. Other cohort studies have shown similar associations between smoking and risk ([@bib2]; [@bib38]; [@bib15]; [@bib18]; [@bib35]; [@bib6]; [@bib16]; [@bib44]; [@bib27]; [@bib12]), and a recent meta-analysis of prospective studies estimated combined hazard ratios of 1.12 for current smoking and 1.09 for former smoking ([@bib12]). In our analysis, there was no dose-response with number of cigarettes smoked daily. Some ([@bib38]; [@bib15]; [@bib6]; [@bib44]) but not all ([@bib2]; [@bib27]; [@bib12]) prior prospective studies have observed a positive trend between number of cigarettes and risk. While it is possible that the lack of a dose--response relationship in the NIH-AARP cohort could be due to the lack of a true association between smoking and breast cancer risk, this is unlikely given the consistency of associations for current and former smoking with those from previous prospective studies, including those that observed dose--response relationships with number of cigarettes smoked. Another possibility is that dose-response was not observed due to the small magnitude of the overall smoking association. Additionally, misclassification of the number of cigarettes smoked may have affected the results. Misclassification could have arisen due to improper recall of number of cigarettes smoked, the use of a single number to approximate dose when the number of cigarettes smoked daily may have varied over decades, or variation over time in cigarette brands, formulations, filters, and manufacturing processes that changed the dose of carcinogens ingested per day even if the same number of cigarettes was smoked per day. However, it is difficult to tell whether any of these reasons affected the associations we observed. The lack of association between time since quitting smoking and risk was similar to most previous prospective studies ([@bib38]; [@bib15]; [@bib6]; [@bib44]; [@bib12]), except for one ([@bib27]) that observed lower risk as time since quitting increased.

The association between smoking and risk is weak in comparison to other breast cancer risk factors, and previous investigations ([@bib17]) have raised the suggestion that associations between smoking and risk may be due to confounding, in particular, due to alcohol consumption. Alcohol is a potentially strong confounder owing to its strong relationships with smoking ([@bib31]) and breast cancer risk ([@bib17]; [@bib7]). In the NIH-AARP cohort, alcohol use was associated with risk in a dose-response manner, such that women who drank \>35 g alcohol per day had 35% greater risk than non-drinkers ([@bib23]). [@bib12] showed that the association between smoking and risk was unchanged after adjusting for recency of alcohol use (never, former, current use), but such broad categories leave potential for residual confounding by alcohol dose. In our analysis, the association between smoking and risk was still observed after adjusting for the amount of alcohol consumed. Further, we estimated associations within strata of alcohol use, with the hypothesis that if the association with smoking was due to confounding by increasing alcohol dose, associations within strata of alcohol use would be null. We found that risk associated with current smoking was elevated across all strata of alcohol use, but risk associated with former smoking was more variable. Together with the results from the study by [@bib12], these results suggest that the association between smoking and risk is likely not due to confounding by alcohol. However, studies with sufficient data to simultaneously address issues of recency and dose of both smoking and alcohol use are needed to fully address this concern, particularly as it relates to former smoking and risk.

We evaluated interactions between smoking and a number of risk factors; many of the weaker variations in association may have been due to chance. Smoking-associated risks differed according to family history of breast cancer, where increased risks were only observed among women without a family history. This was consistent with the data from [@bib38], who reported 39% increased risk for current smoking among postmenopausal women without a family history but no association among women with a family history. Two other studies did not find interaction between smoking and family history ([@bib6]; [@bib12]), but stratified estimates were not shown; therefore, it is unknown whether the estimates were consistent with our findings. In women at high risk of a specific type of familial breast cancer, *BRCA1/BRCA2* mutation carriers, current smoking was not associated with increased risk ([@bib13]; [@bib32]; [@bib14]), which is consistent with our finding of no smoking-associated risk among women with a family history, although smoking was associated with increased risk among mutation carriers in one study ([@bib3]). The potential mechanism that would result in smoking-associated risk only among those without a family history of breast cancer is unknown. It could be hypothesised that smoking and familial breast cancer contribute to risk through the same pathway, and if that pathway is activated by factors related to family history there cannot be further activation by smoking. It is also possible that the differences we observed were due to chance. Greater exploration of the role of genetic factors in smoking-associated breast carcinogenesis is needed to understand possible effect modification by family history.

In this cohort, increased risk due to smoking was also higher among women with late ages at menarche, but there are scant data from other studies to support this result. Of the two previous prospective studies that examined smoking risks stratified by age at menarche, one ([@bib15]) showed similar results---smoking was associated with increased risk among women who reached menarche at ⩾13 years but not women with menarche at \<13 years. However, this was based on a small number of cases (*N*=478) and may have been due to chance. Another study found no differences in smoking-associated risk by age at menarche ([@bib6]).

Biologically, interaction between smoking and reproductive development is plausible. Pubertal breast development generally begins prior to menarche and marks a time of increased epithelial cell proliferation ([@bib22]). As such, this may be a critical time for susceptibility to carcinogens. Other investigations point towards the importance of the timing of smoking initiation in relation to reproductive development. A recent meta-analysis reported positive associations between young age at smoking initiation and risk and smoking before first birth and risk ([@bib12]). Studies have also reported that risk was elevated among women who started smoking prior to menarche ([@bib15]; [@bib12]), and that risk increased with the number of years of smoking between menarche and first birth ([@bib44]).We were unable to evaluate the relationship between age at smoking initiation and risk in this cohort, or the effect of smoking initiation in relation to menarche or first birth. The relative importance of each reproductive milestone in relation to smoking and risk remains to be determined, but this and other studies to date indicate that smoking during these time periods may contribute to breast carcinogenesis. In both instances where we detected interaction, the increased risks were among subgroups that were at relatively lower risk (i.e., women without a family history of breast cancer and women with later age at menarche). It may be possible that increased risks due to smoking are more likely to be detected among women at low risk; however, this pattern was not consistent for all breast cancer risk factors in the stratified analyses.

There was little evidence to suggest that smoking was associated with risk of specific types of breast cancer, although risks were somewhat stronger for women with distant metastases, ER+/PR− tumours, and lobular breast tumours. Previous studies have been inconsistent, with several reporting stronger associations between smoking and ER+ as compared with ER− tumours ([@bib2]; [@bib27]; [@bib12]) and one reporting a strong positive association between smoking and ER− but not ER+ tumours ([@bib29]). Studies that examined risk using combined ER/PR status found elevated risk of ER+/PR+ ([@bib27]) and ER−/PR−([@bib29]) tumours, but not ER+/PR− tumours. Differences by disease stage and histology have been similarly inconsistent ([@bib29]; [@bib27]; [@bib12]). Heterogeneity according to other tumour characteristics, such as molecular subtype, may exist. Studies with an emphasis on tissue collection are needed to investigate this possibility.

Our study was limited by the fact that smoking status and other covariates were assessed at baseline and do not account for changes during the follow-up period. Associations between smoking status and risk were similar when we compared the first 5 years of follow-up with the second 5 years, suggesting that changes that may have occurred during follow-up did not affect relative risks. In addition, information regarding passive smoking was not collected. Others have found that inclusion of passive smokers with never smokers yields a similar, if slightly attenuated, association ([@bib8]; [@bib38]; [@bib27]). Thus, if passive smoking affected this analysis it is likely that the association between active smoking and risk is stronger than what we reported here.

Smoking duration was not assessed on the baseline questionnaire and we were unable to evaluate whether breast cancer risk increased linearly with number of years of smoking, as has been reported by some studies ([@bib15]; [@bib35]; [@bib6]; [@bib27]) but not others ([@bib38]; [@bib12]). Among previous studies that have evaluated both number of cigarettes (dose) and smoking duration, results for these exposures have been inconsistent: dose and duration trends were similar in four studies ([@bib15]; [@bib6]; [@bib44]; [@bib12]) and dissimilar in three ([@bib2]; [@bib38]; [@bib27]). Thus, we cannot infer from the lack of association with number of cigarettes smoked that there is also no association with duration in the NIH-AARP population. Hormone receptor status was only available for a subset of participants; thus, these analyses were less precise than those using the full cohort. Finally, we were unable to examine age at smoking initiation, which may be an important predictor of smoking-associated risk. Further examination of when women begin smoking, in concert with the timing of menarche and first birth, may provide insight as to the mechanism by which smoking is associated with breast cancer risk.

This study also had several strengths. Smoking was assessed prospectively, reducing the potential for recall bias. We used both adjustment and stratification to evaluate potential confounding by alcohol dose and found that neither approach was able to explain the smoking association with risk. This analysis included \>7000 cases, more than most previous prospective studies of smoking and breast cancer risk, allowing for precise estimation of stratified associations and associations between smoking and specific breast cancer types. Finally, we conducted several sensitivity analyses to address potential biases due to women with poor health, respiratory diseases linked to smoking, or changes in risk factor status over the follow-up period. We found no evidence that these factors influenced the results.

Conclusion
==========

Smoking status was positively associated with breast cancer risk in this cohort, but there was no dose--response trend with the number of cigarettes smoked per day or time since quitting. Risks were modified by family history of breast cancer and age at menarche, but additional research evaluating effects of smoking on the genome and on breast tissue during different stages of reproductive development are needed to better understand these findings.
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![**The relationship between smoking and breast cancer risk was examined in 186 150 female, postmenopausal participants in the NIH-AARP Diet and Health Study cohort.** Exclusion criteria are shown in the figure.](bjc2014132f1){#fig1}

![**Association between smoking and postmenopausal breast cancer risk, stratified by breast cancer risk factors.** The association between current (shown in **A**) and former (**B**) smoking and breast cancer risk, in comparison to never smoking, is shown stratified by known breast cancer risk factors. Associations were estimated using data from 186 150 postmenopausal women in the NIH-AARP Diet and Health Study. The *P*-value for interaction (*P*-int, at far right) was estimated using the likelihood ratio test by comparing models containing a multiplicative interaction term between smoking status (never, current, former) and the risk factor of interest with the models with no interaction term.](bjc2014132f2){#fig2}

###### Cigarette smoking and postmenopausal breast cancer risk in the NIH-AARP Diet and Health Study, 1995--2006

                                                            **Person-years**   **Cases**   **HR (95% CI)**[a](#t1-fn2){ref-type="fn"}
  --------------------------------------------------------- ------------------ ----------- --------------------------------------------
  **Smoking status**                                                                       
  Never                                                     827 507            3301        1.00 (reference)
  Former                                                    669 087            2912        1.07 (1.01--1.13)
  Current                                                   290 375            1268        1.19 (1.10--1.28)
  **Cigarettes smoked per day**                                                            
  Never                                                     827 507            3301        1.00 (reference)
  **Former smokers**                                                                       
  1--10                                                     258 936            1105        1.07 (0.99--1.15)
  11--20                                                    203 078            830         1.00 (0.92--1.08)
  21--30                                                    104 912            498         1.18 (1.07--1.31)
  31--40                                                    60 464             295         1.19 (1.05--1.35)
  ⩾41                                                       41 697             184         1.05 (0.89--1.23)
  *P*-trend                                                                                0.10
  **Current smokers**                                                                      
  1--10                                                     90 146             394         1.19 (1.06--1.34)
  11--20                                                    123 196            556         1.22 (1.11--1.35)
  21--30                                                    51 707             210         1.06 (0.91--1.23)
  31--40                                                    19 946             88          1.12 (0.88--1.41)
  ⩾41                                                       5379               20          0.92 (0.57--1.49)
  *P*-trend                                                                                0.15
  **Years since quit smoking[b](#t1-fn3){ref-type="fn"}**                                  
  Never                                                     827 507            3301        1.00 (reference)
  ⩾10                                                       472 406            2058        1.04 (0.98--1.11)
  5--9                                                      120 876            543         1.19 (1.08--1.31)
  1--4                                                      75 805             311         1.09 (0.96--1.24)
  *P*-trend                                                                                0.09

Abbreviations: CI=confidence interval; HR=hazard ratio.

Adjusted for age at study entry, education level, race/ethnicity, age at menarche, nulliparity/age at first birth, type of and age at menopause, menopausal hormone therapy use, grams of alcohol per day, BMI, frequency of vigorous physical activity, previous breast biopsy, and family history of breast cancer.

Estimated among former and never smokers.

###### Joint associations[a](#t2-fn2){ref-type="fn"} of smoking and family history of breast cancer with postmenopausal breast cancer risk

                                             **Family history of breast cancer**  
  ----------------------------------------- ------------------------------------- -------------------
  **Smoking status**                                                              
  **Never**                                                                       
   HR (95% CI)[b](#t2-fn3){ref-type="fn"}             1.00 (reference)             1.56 (1.42--1.71)
   Cases                                                    2551                          617
   Person-years                                            689 876                      103 053
  **Former**                                                                      
   HR (95% CI)[b](#t2-fn3){ref-type="fn"}             1.08 (1.01--1.14)            1.60 (1.45--1.77)
   Cases                                                    2289                          506
   Person-years                                            558 410                      83 133
  **Current**                                                                     
   HR (95% CI)[b](#t2-fn3){ref-type="fn"}             1.24 (1.14--1.34)            1.49 (1.27--1.75)
   Cases                                                    1023                          174
   Person-years                                            242 761                      33 628

Abbreviations: CI=confidence interval; HR=hazard ratio.

*P*-interaction=0.03.

Adjusted for age at study entry, education level, race/ethnicity, age at menarche, nulliparity/age at first birth, age at and type of menopause, menopausal hormone therapy use, grams of alcohol consumed per day, BMI, frequency of vigorous physical activity, and previous breast biopsy.

###### Joint associations[a](#t3-fn2){ref-type="fn"} of smoking and age at menarche with postmenopausal breast cancer risk

                                             **Age at menarche (years)**                      
  ----------------------------------------- ----------------------------- ------------------- -------------------
  **Smoking status**                                                                          
  **Never**                                                                                   
   HR (95% CI)[b](#t3-fn3){ref-type="fn"}         1.00 (reference)         0.98 (0.91--1.06)   0.77 (0.66--0.89)
   Cases                                                1665                     1374                 251
   Person-years                                        401 836                  344 288             78 524
  **Former**                                                                                  
   HR (95% CI)[b](#t3-fn3){ref-type="fn"}         1.07 (0.99--1.15)        1.00 (0.92--1.08)   1.04 (0.91--1.20)
   Cases                                                1456                     1198                 255
   Person-years                                        326 005                  280 890             60 495
  **Current**                                                                                 
   HR (95% CI)[b](#t3-fn3){ref-type="fn"}         1.14 (1.03--1.27)        1.15 (1.03--1.28)   1.21 (0.99--1.47)
   Cases                                                 620                      515                 131
   Person-years                                        142 563                  118 010             29 113

Abbreviations: CI=confidence interval; HR=hazard ratio.

*P*-interaction=0.03.

Adjusted for age at study entry, education level, race/ethnicity, nulliparity/age at first birth, age at and type of menopause, menopausal hormone therapy use, grams of alcohol consumed per day, BMI, frequency of vigorous physical activity, previous breast biopsy, and family history of breast cancer.

###### Smoking status and risk of specific breast cancer types in the NIH-AARP Diet and Health Study

                                                                                              **Smoking status**  **Cases (*****N***)   **HR (95% CI)**[a](#t4-fn2){ref-type="fn"}    ***P*****-heterogeneity**
  ------------------------------------------------------------------------------------------ -------------------- --------------------- -------------------------------------------- ---------------------------
  **Disease stage at diagnosis**                                                                                                                                                     
  Localised                                                                                         Never         1571                  1.00 (reference)                                        0.22
                                                                                                    Former        1404                  1.07 (0.99--1.16)                                          
                                                                                                   Current        625                   1.21 (1.09--1.34)                                          
  Regional spread                                                                                   Never         563                   1.00 (reference)                                           
                                                                                                    Former        496                   1.10 (0.96--1.26)                                          
                                                                                                   Current        217                   1.18 (0.99--1.41)                                          
  Distant metastases                                                                                Never         55                    1.00 (reference)                                           
                                                                                                    Former        67                    1.56 (1.06--2.30)                                          
                                                                                                   Current        42                    2.05 (1.30--3.23)                                          
  **Histology**                                                                                                                                                                      
  Ductal                                                                                            Never         2272                  1.00 (reference)                                        0.55
                                                                                                    Former        2147                  1.09 (1.02--1.17)                                          
                                                                                                   Current        757                   1.17 (1.07--1.28)                                          
  Lobular                                                                                           Never         357                   1.00 (reference)                                           
                                                                                                    Former        332                   1.05 (0.89--1.24)                                          
                                                                                                   Current        130                   1.31 (1.05--1.62)                                          
  Mixed ductal-lobular                                                                              Never         280                   1.00 (reference)                                           
                                                                                                    Former        252                   1.01 (0.84--1.21)                                          
                                                                                                   Current        88                    1.03 (0.79--1.35)                                          
  **Hormone receptor expression**[b](#t4-fn3){ref-type="fn"}^,^[c](#t4-fn4){ref-type="fn"}                                                                                           
  ER+/PR+                                                                                           Never         1148                  1.00 (reference)                                        0.40
                                                                                                    Former        995                   1.04 (0.95--1.14)                                          
                                                                                                   Current        369                   1.02 (0.89--1.17)                                          
  ER+/PR-                                                                                           Never         222                   1.00 (reference)                                           
                                                                                                    Former        212                   1.13 (0.92--1.39)                                          
                                                                                                   Current        109                   1.37 (1.05--1.80)                                          
  ER−/PR−                                                                                           Never         260                   1.00 (reference)                                           
                                                                                                    Former        219                   1.08 (0.88--1.31)                                          
                                                                                                   Current        93                    1.05 (0.81--1.38)                                          
  **Tumour grade**                                                                                                                                                                   
  Low                                                                                               Never         675                   1.00 (reference)                                        0.90
                                                                                                    Former        675                   1.12 (0.99--1.25)                                          
                                                                                                   Current        236                   1.19 (1.02--1.40)                                          
  Intermediate                                                                                      Never         1277                  1.00 (reference)                                           
                                                                                                    Former        1151                  1.03 (0.95--1.13)                                          
                                                                                                   Current        408                   1.14 (1.01--1.28)                                          
  High                                                                                              Never         868                   1.00 (reference)                                           
                                                                                                    Former        809                   1.10 (0.99--1.22)                                          
                                                                                                   Current        293                   1.18 (1.03--1.36)                                          

Abbreviations: CI=confidence interval; HR=hazard ratio.

Adjusted for age at study entry, education level, race/ethnicity, age at menarche, nulliparity/age at first birth, type of and age at menopause, menopausal hormone therapy use, grams of alcohol per day, BMI, frequency of vigorous physical activity, previous breast biopsy, and family history of breast cancer.

Estimated only among women residing in areas that reported hormone receptor data (California, Louisiana, New Jersey, North Carolina, Arizona, Nevada, Atlanta, Georgia, and Detroit, Michigan).

ER−/PR+ association not estimated due to low case numbers.
